Tumor News and Research

RSS

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced an expanded clinical focus to include an autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.

6 Jun 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

New UH Seidman Cancer Center center to offer latest treatments and technology

University Hospitals (UH) Seidman Cancer Center, Northeast Ohio's first and only freestanding cancer hospital, opens to patients on June 6. The ten-story, 150-bed cancer hospital will house the latest cancer-fighting treatments and technology – all in a patient-centered, healing-focused environment.

6 Jun 2011

Researcher finds thyroid cancer gene inhibits spread of malignant cells

A mutant gene long thought to accelerate tumor growth in thyroid cancer patients actually inhibits the spread of malignant cells, showing promise for novel cancer therapies, a Mayo Clinic study has found.

6 Jun 2011

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.

6 Jun 2011

New targeted therapy may halt tumor growth in men with advanced prostate cancer

A new targeted therapy for prostate cancer halts tumor growth in animals with advanced prostate cancer that is resistant to hormone therapy, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease.

6 Jun 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the presentation of favorable clinical data for SAR3419 in the treatment of B-cell non-Hodgkin's lymphoma (NHL).

6 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center.

4 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011

Study links loss of PTEN gene with patient's response to melanoma therapy

Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4.

4 Jun 2011

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

4 Jun 2011

Tumor News and Research

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Cancer risk assessment in Lynch syndrome

New UH Seidman Cancer Center center to offer latest treatments and technology

Researcher finds thyroid cancer gene inhibits spread of malignant cells

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

New targeted therapy may halt tumor growth in men with advanced prostate cancer

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Study links loss of PTEN gene with patient's response to melanoma therapy

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News